ES2044087T3 - Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada. - Google Patents
Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.Info
- Publication number
- ES2044087T3 ES2044087T3 ES89301888T ES89301888T ES2044087T3 ES 2044087 T3 ES2044087 T3 ES 2044087T3 ES 89301888 T ES89301888 T ES 89301888T ES 89301888 T ES89301888 T ES 89301888T ES 2044087 T3 ES2044087 T3 ES 2044087T3
- Authority
- ES
- Spain
- Prior art keywords
- dihydro
- stabilized
- composition
- cetoprostaglandine
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000000258 13,14-dihydro-15-keto-prostaglandin D2 derivatives Chemical class 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 239000011872 intimate mixture Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63045622A JP2597629B2 (ja) | 1988-02-26 | 1988-02-26 | １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2044087T3 true ES2044087T3 (es) | 1994-01-01 |
Family
ID=12724473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES89301888T Expired - Lifetime ES2044087T3 (es) | 1988-02-26 | 1989-02-24 | Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0330511B1 (en:Method) |
| JP (1) | JP2597629B2 (en:Method) |
| KR (1) | KR970005170B1 (en:Method) |
| AT (1) | ATE79260T1 (en:Method) |
| AU (1) | AU612791B2 (en:Method) |
| CA (1) | CA1314483C (en:Method) |
| DE (1) | DE68902401T2 (en:Method) |
| ES (1) | ES2044087T3 (en:Method) |
| GB (1) | GB2216004A (en:Method) |
| GR (1) | GR3005933T3 (en:Method) |
| NZ (1) | NZ228111A (en:Method) |
| OA (1) | OA09236A (en:Method) |
| ZA (1) | ZA891410B (en:Method) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236907A (en) * | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
| ES2052735T3 (es) * | 1987-09-18 | 1994-07-16 | R Tech Ueno Ltd | Un metodo para producir un agente hipotensor ocular. |
| US6420422B1 (en) | 1987-09-18 | 2002-07-16 | Sucampo Pharmaceuticals, Inc. | Ocular hypotensive agents |
| US5166178B1 (en) * | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5212200A (en) * | 1987-09-18 | 1993-05-18 | R-Tech Ueno, Ltd. | Ocular hypotensive agents |
| US5565492A (en) * | 1988-07-18 | 1996-10-15 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| EP0569046B1 (en) * | 1988-09-06 | 2002-11-13 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5194429A (en) * | 1988-10-01 | 1993-03-16 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
| ATE162074T1 (de) * | 1988-10-01 | 1998-01-15 | R Tech Ueno Ltd | Oculare hypotensive mittel |
| US5234954A (en) * | 1989-07-27 | 1993-08-10 | K.K. Ueno Seiyaku Oyo Kenkyujo | Treatment of hyperlipidemia with 15-keto-prostaglandin compounds |
| DE69019431T2 (de) * | 1989-07-27 | 1995-09-14 | Ueno Seiyaku Oyo Kenkyujo Kk | Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions. |
| DE69018903T2 (de) * | 1989-08-09 | 1995-08-24 | Ueno Seiyaku Oyo Kenkyujo Kk | Verwendung von Prostansäurederivaten zur Herstellung von Arzneimitteln zur Verbesserung der Ausscheidung von Nichtprotein in die Därme. |
| CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
| US5254588A (en) * | 1989-11-22 | 1993-10-19 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds |
| CA2030344C (en) * | 1989-11-22 | 2000-04-18 | Ryuji Ueno | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds |
| CA2030346C (en) * | 1989-11-22 | 2000-04-11 | Ryuji Ueno | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds |
| US5256696A (en) * | 1989-11-22 | 1993-10-26 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds |
| CA2031469A1 (en) * | 1989-12-28 | 1991-06-29 | Larry A. Wheeler | Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension |
| TW249226B (en:Method) * | 1990-04-04 | 1995-06-11 | Aderk Ueno Kk | |
| CA2046069C (en) * | 1990-07-10 | 2002-04-09 | Ryuji Ueno | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
| ES2093774T3 (es) * | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US6184250B1 (en) | 1993-08-03 | 2001-02-06 | Alcon Laboratories, Inc. | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
| US5807892A (en) * | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US5698733A (en) * | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
| US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| AU7672096A (en) | 1995-06-07 | 1998-06-03 | Alcon Laboratories, Inc. | Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy |
| US6096783A (en) * | 1998-12-15 | 2000-08-01 | Alcon Laboratories, Inc. | Cyclobutane prostaglandin analogues as ocular hypotensive agents |
| US6211226B1 (en) | 1998-12-17 | 2001-04-03 | Alcon Laboratories, Inc. | 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
| WO2004037268A1 (en) * | 2002-10-23 | 2004-05-06 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
| WO2005044276A1 (ja) * | 2003-11-07 | 2005-05-19 | Senju Pharmaceutical Co., Ltd. | プロスタグランジン含有医薬組成物 |
| EP1985298A1 (en) | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Ophtalmic oil-in-water emulsions containing prostaglandins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5910525A (ja) * | 1982-06-21 | 1984-01-20 | Teisan Seiyaku Kk | プロスタグランジンｅの安定化組成物 |
| JPH0819004B2 (ja) * | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | 徐放性医薬製剤 |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| CA1323364C (en) | 1987-01-28 | 1993-10-19 | Ryuzo Ueno | Prostaglandins e and anti ulcer agents containing same |
| CA1324129C (en) | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
| DE3869471D1 (de) | 1987-05-15 | 1992-04-30 | Ueno Seiyaku Oyo Kenkyujo Kk | Fiebersteigende zusammensetzung. |
| ES2052735T3 (es) | 1987-09-18 | 1994-07-16 | R Tech Ueno Ltd | Un metodo para producir un agente hipotensor ocular. |
-
1988
- 1988-02-26 JP JP63045622A patent/JP2597629B2/ja not_active Expired - Fee Related
-
1989
- 1989-02-23 ZA ZA891410A patent/ZA891410B/xx unknown
- 1989-02-23 NZ NZ228111A patent/NZ228111A/xx unknown
- 1989-02-23 AU AU30298/89A patent/AU612791B2/en not_active Ceased
- 1989-02-23 CA CA000591913A patent/CA1314483C/en not_active Expired - Fee Related
- 1989-02-24 GB GB8904232A patent/GB2216004A/en not_active Withdrawn
- 1989-02-24 DE DE8989301888T patent/DE68902401T2/de not_active Expired - Lifetime
- 1989-02-24 EP EP89301888A patent/EP0330511B1/en not_active Expired - Lifetime
- 1989-02-24 OA OA59533A patent/OA09236A/xx unknown
- 1989-02-24 ES ES89301888T patent/ES2044087T3/es not_active Expired - Lifetime
- 1989-02-24 AT AT89301888T patent/ATE79260T1/de not_active IP Right Cessation
- 1989-02-25 KR KR89002257A patent/KR970005170B1/ko not_active Expired - Fee Related
-
1992
- 1992-10-12 GR GR920402253T patent/GR3005933T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2597629B2 (ja) | 1997-04-09 |
| KR970005170B1 (en) | 1997-04-14 |
| KR890012654A (ko) | 1989-09-18 |
| DE68902401T2 (de) | 1992-12-10 |
| EP0330511A2 (en) | 1989-08-30 |
| NZ228111A (en) | 1991-02-26 |
| GB8904232D0 (en) | 1989-04-12 |
| EP0330511B1 (en) | 1992-08-12 |
| JPH01221317A (ja) | 1989-09-04 |
| AU3029889A (en) | 1989-08-31 |
| GB2216004A (en) | 1989-10-04 |
| CA1314483C (en) | 1993-03-16 |
| AU612791B2 (en) | 1991-07-18 |
| ZA891410B (en) | 1989-11-29 |
| GR3005933T3 (en:Method) | 1993-06-07 |
| EP0330511A3 (en) | 1989-10-18 |
| ATE79260T1 (de) | 1992-08-15 |
| DE68902401D1 (de) | 1992-09-17 |
| OA09236A (en) | 1992-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2044087T3 (es) | Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada. | |
| PL303937A1 (en) | Application of an antiestrogen compound and pharmaceutical agent | |
| FI906204L (fi) | Menetelmä farmaseuttisesti vaikuttavien peptidiyhdisteiden valmistamiseksi | |
| IL136249A0 (en) | Suppository containing an acid-labile active compound | |
| LU90943I2 (fr) | Kineret-anakinra et ses dérivés pharmaceutiquement acceptables | |
| FI893520L (fi) | Menetelmä intravenoosisen farmaseuttisen koostumuksen valmistamiseksi | |
| FI911646A7 (fi) | DTPA-monoamideja, näitä yhdisteitä sisältäviä farmaseuttisia aineita, niiden käyttö ja menetelmä niiden valmistamiseksi | |
| ES522107A0 (es) | Procedimiento para preparar composiciones farmaceuticas inyectadas que contienen derivados de 2-metil-3-carboxamida-4-hidroxitiazina 1,1-dioxido. | |
| FI913775A7 (fi) | 17-asemassa substituoidut kortikoidi-17-alkyyliakrbonaatit, menetelmä niiden valmistamiseksi ja niitä sisältävät lääkeaineet | |
| IE880061L (en) | 1,2,4,5-tetrasubstituted benzene derivatives | |
| FI952482L (fi) | Uusi menetelmä taksaanijohdannaisten valmistamiseksi, näin saadut johdannaiset ja niitä sisältävät koostumukset | |
| DE69828043D1 (de) | Fluoridfreie zahnremineralisierung | |
| JPS5753414A (en) | Stabilized medicinal composition | |
| DE3686022D1 (de) | Monosaccharide enthaltende zusammensetzung zum heilen von wunden. | |
| IT8348950A0 (it) | Composizione farmaceutica a base di antibiotici beta-lattamici,procedimento per prepararla e metodo per stabilizzarla | |
| MY104979A (en) | [ 5(6)(ih-azole-1-ylmethyl) benzimidazole] carbamates. | |
| FI853648A7 (fi) | Menetelmä farmaseuttisesti aktiivisten 4,5-dihydro-4-okso-2-/ (2-trans-fenyylisyklopropyyli)amino/ -3-furaanikarboksyylihappojen ja niiden johdannaisten valmistamiseksi. | |
| IL105475A0 (en) | Pharmaceutical compositions containing 1alpha,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 for treating osteoporosis | |
| ES2004097A6 (es) | Procedimiento de preparacion de un nuevo derivado triciclico denominado acido 5-(3-cloro-6-metil-5,5-dioxo-6,11-dihidro-(c,f)-dibenzo-(1,2)-tiazepin-11-il)amino)-pentanoico | |
| FI852743A7 (fi) | Asetyleenisiä fenoksipropanolijohdannaisia ja farmaseuttisia koostumuksia hypertoniahoitamiseksi. | |
| DE3766885D1 (en) | Chlorpheniramine therapie. | |
| NO178096C (no) | Fremgangsmåte for fremstilling av et transdermalt leveringssystem for en farmasöytisk aktiv forbindelse | |
| FI895923A7 (fi) | Oraalinen, vähentyneen värjäytyvyyden aiheuttava menetelmä plakin ehkäisemiseksi | |
| IT1229178B (it) | Procedimento per l'ottenimento di una miscela di ribonucleotidi. | |
| SE8800461L (sv) | Farmaceutisk komposition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 330511 Country of ref document: ES |